| 2.2 0.38 (20.88%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.56 |
1-year : | 3 |
| Resists | First : | 2.2 |
Second : | 2.56 |
| Pivot price | 2.02 |
|||
| Supports | First : | 1.95 |
Second : | 1.79 |
| MAs | MA(5) : | 1.92 |
MA(20) : | 2.02 |
| MA(100) : | 2.16  |
MA(250) : | 1.66 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 40.5 |
D(3) : | 23.9 |
| RSI | RSI(14): 61.5 |
|||
| 52-week | High : | 2.95 | Low : | 0.98 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TXMD ] has closed below upper band by 11.7%. Bollinger Bands are 25.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.2 - 2.22 | 2.22 - 2.23 |
| Low: | 1.82 - 1.84 | 1.84 - 1.85 |
| Close: | 2.18 - 2.2 | 2.2 - 2.22 |
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Tue, 12 May 2026
TherapeuticsMD (TXMD) details Q1 2026 results and strategic review - Stock Titan
Mon, 30 Mar 2026
TherapeuticsMD Announces Full Year 2025 Financial Results - Yahoo Finance
Sat, 14 Feb 2026
TXMD Technical Analysis & Stock Price Forecast - Intellectia AI
Wed, 11 Feb 2026
TherapeuticsMD, Inc. (TXMD) stock price prediction 2026–2030 - Bitget
Wed, 12 Nov 2025
TherapeuticsMD Announces Third Quarter 2025 Financial Results - Yahoo Finance
Wed, 30 Aug 2023
symbol__ Stock Quote Price and Forecast - CNN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 12 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 7.4 (%) |
| Held by Institutions | 33.9 (%) |
| Shares Short | 53 (K) |
| Shares Short P.Month | 52 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.31 |
| Profit Margin | 5.3 % |
| Operating Margin | -28.5 % |
| Return on Assets (ttm) | -3 % |
| Return on Equity (ttm) | 0.3 % |
| Qtrly Rev. Growth | 84.1 % |
| Gross Profit (p.s.) | 0.28 |
| Sales Per Share | 0.28 |
| EBITDA (p.s.) | -0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 3 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | 220 |
| PEG Ratio | 0 |
| Price to Book value | 0.94 |
| Price to Sales | 7.59 |
| Price to Cash Flow | 9.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|